PET Imaging in Pulmonary Hypertension
Arteriosclerosis, Thrombosis, and Vascular Biology · 2026
DOI: 10.1161/atvbaha.126.324761 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Arteriosclerosis, Thrombosis, and Vascular Biology, 2026. Verfasst von Mandy M T van Leent und 6 weiteren Autor:innen. Beteiligte Einrichtung: BioMedical Engineering and Imaging Institute (M.M.T.v.L., T.S.H., P.M.R., M.G.T.), Icahn School of Medicine at Mount Sinai, New York, NY. Hauptthemen laut MEDLINE: Positron-Emission Tomography, Pulmonary Artery, Hypertension, Pulmonary, Pulmonary Arterial Hypertension. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.
Abstract (Originalsprache)
Pulmonary hypertension comprises a heterogeneous group of diseases characterized by elevated pulmonary arterial pressures and progressive right ventricular (RV) remodeling, with RV failure as the principal determinant of outcome. This review discusses positron emission tomography (PET) imaging across pulmonary hypertension, with particular emphasis on pulmonary arterial hypertension, in which pulmonary vascular remodeling and RV adaptation are central disease features. Although echocardiography and cardiac magnetic resonance imaging provide robust assessment of RV structure, function, and fibrosis, they are limited in detecting early molecular alterations that precede overt dysfunction. PET offers a unique opportunity to visualize these processes. In particular, [ 18 F]FDG PET has demonstrated a shift in RV substrate utilization from fatty acid oxidation toward glycolysis, reflecting metabolic stress and maladaptation. More recently, fibroblast activation protein inhibitor PET has emerged as a promising modality, with first-in-human studies in pulmonary arterial hypertension demonstrating uptake in the RV and pulmonary vasculature, consistent with active remodeling. Beyond fibroblast activation, additional metabolic and immunologic targets may provide complementary insight into pulmonary vascular disease activity, RV remodeling, and treatment response. Together, these advances position PET as a powerful tool for early detection, phenotyping, and risk stratification in pulmonary hypertension, with particular relevance for pulmonary arterial hypertension.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- BioMedical Engineering and Imaging Institute (M.M.T.v.L., T.S.H., P.M.R., M.G.T.), Icahn School of Medicine at Mount Sinai, New York, NY.
- Cardiovascular Research Institute (M.M.T.v.L., T.S.H., H.M., K.I., M.G.T.), Icahn School of Medicine at Mount Sinai, New York, NY.
- Department of Diagnostic, Molecular, and Interventional Radiology (M.M.T.v.L., P.M.R., M.G.T.), Icahn School of Medicine at Mount Sinai, New York, NY.
- Mount Sinai Fuster Heart Hospital (S.S., M.G.T.), Icahn School of Medicine at Mount Sinai, New York, NY.
ORCID-Profile: Mandy M T van Leent, Sanjay Sivalokanathan, Philip M Robson, Kiyotake Ishikawa, Maria Giovanna Trivieri
Förderung
- NHLBI NIH HHS
Zitieren
APA
van Leent, M. M. T., St Hillaire, T., Sivalokanathan, S., Morita, H., Robson, P. M., Ishikawa, K., & Trivieri, M. G. (2026). PET Imaging in Pulmonary Hypertension. Arteriosclerosis, Thrombosis, and Vascular Biology. https://doi.org/10.1161/atvbaha.126.324761
Vancouver
van Leent MMT, St Hillaire T, Sivalokanathan S, Morita H, Robson PM, Ishikawa K, et al. PET Imaging in Pulmonary Hypertension. Arteriosclerosis, Thrombosis, and Vascular Biology. 2026. doi:10.1161/atvbaha.126.324761
BibTeX
@article{vanLeent2026,
author = {van Leent, Mandy M T and St Hillaire, Trea and Sivalokanathan, Sanjay and Morita, Hidetaka and Robson, Philip M and Ishikawa, Kiyotake and Trivieri, Maria Giovanna},
title = {PET Imaging in Pulmonary Hypertension},
journal = {Arteriosclerosis, Thrombosis, and Vascular Biology},
year = {2026},
doi = {10.1161/atvbaha.126.324761}
}
EUVIMED